Effects of anticoagulants on bone

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 2, 2004, Pages 151-158

  Simon, Ryan R ^a   Shaughnessy, Stephen G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Animal models; Bone histomorphometry; Epidemiology; Heparin; Osteoporosis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; BONE DENSITY; BONE DISEASE; CLINICAL RESEARCH; DRUG INDUCED DISEASE; EMBRYOPATHY; HUMAN; LONG TERM EXPOSURE; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 4143149880     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:2:151     Document Type: Review

References (56)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. 2001 Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:S1;S64-S94.
2. Hirsh J. 1991 Heparin. N Engl J Med 324:1565-1574.
3. Griffith CC, Nichols G, Asher JD, Flanagan B. 1965 Heparin osteoporosis. JAMA 193:85-88.
4. Jaffe MD, Willis PW. 1965 Multiple fractures associated with long-term sodium heparin therapy. JAMA 193:152-154.
5. Miller WE, DeWolfe VG. 1966 Osteoporosis resulting from heparin therapy. Cleve Clin Q 33:31-34.
6. Avioli LV. 1975 Heparin induced osteoporosis: an appraisal. Adv Exp Med Biol 52:375-387.
7. Squires JW, Pinch LW. 1979 Heparin-induced spinal fractures. JAMA 241:2417-2418.
8. Rupp WM, McCarthy HB, Rohde TD, et al. 1982 Risk of osteoporosis in patients treated with long-term intravenous heparin. Curr Probl Surg 39:419-422.
9. Monreal M, Olive A, Lafoz E, del Rio L. 1991 Heparins, coumarin, and bone density [letter]. Lancet 338:706.
10. Murphy MS, John PR, Mayer AD, Buckele JA, Kelly DA. 1992 Heparin therapy and bone fractures [letter]. Lancet 340:1098.
11. Dahlman TC. 1993 Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265-1270.
12. Barbour LA, Kick SD, Steiner JF, et al. 1994 A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862-869.
13. Dahlman TC, Sjoberg HE, Ringertz H. 1994 Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170:1315-1320.
14. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. 1994 Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71:7-11.
15. Shefras J, Farquharson RG. 1996 Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 65:171-174.
16. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. 1996 The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 75:254-257.
17. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. 1999 Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999 96:275-282.
18. Beguin S, Lindhout T, Hemker HC. 1988 The mode of action of heparin in plasma. Thromb Haemost 60:457-462.
19. Bates SM. 2002 Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 108:97-106.
20. Chan WS, Anand S, Ginsberg JS. 2000 Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160:191-196.
21. Ginsberg JS, Greer I, Hirsh J. 2001 Use of antithrombotic agents during pregnancy. Chest 119:S1;S122-S131.
22. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. 2002 Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182-186.
23. Muir JM, Andrew M, Hirsh J, et al. 1996 Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:1314-1320.
24. Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI. 1999 A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999 93:1231-1236.
25. Harenberg J. 1990 Pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1990 S:S12-S18.
26. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. 1980 The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255:10081-10090.
27. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. 1980 The binding of low molecular weight heparin to hemostatic enzymes. J Biol Chem 255:10073-10080.
28. Young E, Cosmi B, Weitz J, Hirsh J. 1993 Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 70:625-630.
29. Young E, Wells P, Holloway S, Weitz J, Hirsh J. 1994 Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71:300-304.
30. Nelson-Piercy C, Letsky EA, de Swiet M. 1997 Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176:1062-1068.
31. Casele HL, Laifer SA. 2000 Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med. 9:122-125.
32. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. 1997 A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236-3242.
33. Shaughnessy SG, Young E, Deschamps P, Hirsh J. 1995 The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368-1373.
34. Stenflo J, Fernlund P, Egan W, Roepstorff P. 1974 Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71:2730-2733.
35. Nelsestuen GL, Zytkovicz TH, Howard JB. 1974 The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249:6347-6350.
36. Whitlon DS, Sadowski JA, Suttie JW. 1978 Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17:1371-1377
37. Fasco MJ, Hildebrandt EF, Suttie JW. 1982 Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 257:11210-11212.
38. Choonara IA, Malia RG, Haynes BP, et al. 1988 The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 25:1-7.
39. Trivedi LS, Rhee M, Galivan JH, Fasco MJ. 1988 Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation. Arch Biochem Biophys 264:67-73.
40. Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A. 1977 A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 494:271-276.
41. Malhotra OP, Nesheim ME, Mann KG. 1985 The kinetics of activation of normal and γ-carboxyglutamic acid-deficient prothrombins. J Biol Chem 260:279-287.
42. Maillard C, Berruyer M, Serre CM, Dechavanne M, Delmas PD. 1992 Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 130:1599-1604.
43. Pettifor JM, Benson R. 1975 Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 86:459-462.
44. Hall JG, Pauli RM, Wilson KM. 1980 Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122-140.
45. Fiore CE, Tamburino C, Foti R, Grimaldi D. 1990 Reduced axial bone mineral content in patients taking an oral anticoagulant. South Med J 83:538-542.
46. Philip WJ, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS. 1995 Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 88:635-640.
47. Monreal M, Olive A, Lafoz E, del Rio L. 1991 Heparins, coumarin, and bone density. Lancet 338:706.
48. Resch H, Pietschmann P, Krexner E, Willvonseder R. 1991 Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. Eur Heart J 12:439-441.
49. Sato Y, Honda Y, Kunoh H, Oizumi K. 1997 Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 28:2390-2394.
50. Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ 3rd. 1999 Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 9:441-448.
51. Caraballo PJ, Heit JA, Atkinson EJ, et al. 1999 Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159:1750-1756.
52. Jamal SA, Browner WS, Bauer DC, Cummings SR. 1998 Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 128:829-832.
53. Simon RR, Beaudin SM, Johnston M, Walton KJ, Shaughnessy SG. 2002 Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb Res 105:353-358.
54. Matzsch T, Bergqvist D, Hedner U, Nilsson B, Ostergaard P. 1990 Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 63:505-509.
55. Monreal M, Vinas L, Monreal L, Lavin S, Lafoz E, Angles AM. 1990 Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. Haemostasis 20:204-207.
56. Nishiyama M, Itoh F, Ujiie A. 1997 Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol 74:59-68.